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Objective: To review insulin detemir for clinical use to better manage patients with type 1 
and type 2 diabetes.
Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using 
the terms “insulin analogs,” “insulin detemir” and “long-acting insulin analog.”
Results: Insulin detemir improves glycemic control, based on HbA1C reduction and fasting 
glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has 
lower glycemic variability, with less intra-subject variability in blood glucose levels in patients 
with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to 
oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority 
to other basal insulin options.
Conclusion: Insulin detemir appears to provide better glycemic control with a lower risk of 
hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.
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Introduction
This review examines the most recent MEDLINE search, and updates a previous 
review of insulin detemir compiled through June 30, 2006.1 This long-acting basal 
analog has unique properties including a more consistent pharmacodynamic profile, 
with less glycemic variability, a lower the risk of hypoglycemia and less weight gain. 
Insulin detemir appears to be the most suitable choice of basal insulin for clinicians 
who treat diabetes.
Normalization of glucose levels is the primary goal of managing patients with 
diabetes. The Diabetes Control and Complications Trial (DCCT), and the United 
Kingdom Prospective Diabetes Study (UKPDS), unequivocally demonstrated that tight 
metabolic control reduces the incidence, and also delays the development, of compli-
cations in patients with type 1 and type 2 diabetes, respectively.2–7 The DCCT/EDIC 
(Epidemiology of Diabetes Interventions and Complications) proved that intensive 
diabetes therapy had long-term beneficial effects by reducing the risk of cardiovascular 
disease in patients with type 1 diabetes after 17 years of treatment.8 Intensive therapy 
in the DCCT/EDIC trial was defined as basal insulin with pre-prandial short-acting 
insulin, or continuous insulin infusion. Intensive insulin therapy replicates normal 
physiology, utilizing a long-acting insulin analog, which provides a basal dose of insulin 
throughout the day, and adding short-acting insulin analog for mealtime dosing.
In type 1 diabetes, insulin is fundamental, utilizing a long-acting analog (qd/bid), 
or a continuous, variable, subcutaneous infusion of short-acting analog insulin, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 32
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supplemented with meal time short-acting analog bolus 
therapy. Insulin should be initiated early in the course of 
diabetes to attain optimal glucose control. Intensive man-
agement of type 2 diabetes, as in the Steno-2 Study, was 
associated with an average reduction of cardiovascular 
events by 7.8 years, as well as reduction in nephropathy, 
retinopathy and autonomic neuropathy by about half com-
pared with a conventional multifactorial treatment.9
More recently, three large clinical studies, the Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) trial, the 
Action in Diabetes and Vascular Disease (ADVANCE) trial, 
and the Veterans’ Administration Diabetes Trial (VADT), 
invoked controversy.10 In ACCORD, all 10,251 patients 
were randomly assigned to receive comprehensive intensive 
therapy targeting a glycated hemoglobin level of less than 
6.0% or to receive standard therapy targeting a level of 7.0% 
to 7.9%. With the use of a double two-by-two factorial design, 
4733 patients were randomly assigned to lower their blood 
pressure by receiving either intensive therapy (systolic blood-
pressure target, 120 mmHg) or standard therapy (systolic 
blood-pressure target, 140 mmHg). In addition, 5518 
patients were randomly assigned to receive either fenofibrate 
or placebo while maintaining good control of low-density 
lipoprotein cholesterol with simvastatin. The blood-pressure 
and lipid trials are continuing, and results for these remain 
masked. Of note, in ACCORD, all oral anti-diabetes agents 
(OADs), including multiple sulfonylureas, biguanides, alpha 
glucosidase reductase inhibitors and thiazolidinedione agents, 
were utilized to provide “intensive glycemic control,” and it 
was this multi-drug treatment group that was terminated early, 
due to a higher rate of all cause mortality, although lower 
than predicted. This intensive group had significantly fewer 
nonfatal myocardial infarctions. The results of ADVANCE 
and the VADT conflict with ACCORD and beg the question 
for more uniformity of diabetes management, limiting the 
number of oral agents and utilizing insulin as basal, bolus 
or combinations of both when intensifying blood glucose 
levels.
The rate of hypoglycemic events was significantly more 
in all of these trials when diabetes management was intensi-
fied, irrespective of the use of insulin therapy. Future studies 
will need to examine insulin therapy in type 2 diabetes with 
limited use of OADs, quite possibly to metformin as the lone 
oral agent, since it has already demonstrated cardiovascular 
risk reduction in UKPDS.11 Potentially, a basal bolus arm 
should be considered in type 2 diabetes.
In the future, studies will examine cardiovascular risk 
reduction in type 1 and type 2 diabetes with a greater intent 
to define hypoglycemia as a major contributing cause of 
morbidity and death. Cardiovascular risk reduction trials 
will focus on glucose variability and targeting near-normal 
glycemic levels utilizing strategies and therapies which reduce 
postprandial glucose levels, and lower rates of hypoglycemia 
as well as technologies to better measure hypoglycemia, like 
continuous glucose sensing (CGM).12–15
Hypoglycemia and weight gain are beguiling issues for 
patients with type 1 and 2 diabetes, especially with intensive 
reduction of glucose levels. Theories abound, but there is 
evidence that basal insulin detemir is a predictable basal 
insulin with lower glycemic variability. These unique prop-
erties have been associated with less weight gain compared 
to NPH and glargine.
Glycemic variability
Insulin glargine is a modification of the amino acid sequence 
of human insulin, in that two arginine residues added to the 
C terminus of the B-chain shift the isoelectric point from 
pH 5.4 to 6.719. Insulin glargine is injected as a solute 
in an acidic formulation, forms a microprecipitate in the 
(neutral pH) subcutaneous tissue, and has a prolonged dura-
tion of action due to its slow dissolution of the precipitate. 
Insulin glargine has a prolonged duration of action and 
is indicated for once-daily dosing. The precipitate depot 
represents a potential source of variability.
Insulin detemir’s formulation is remarkably different 
from other basal insulins. The prolonged action of insulin 
detemir is accomplished by attaching a 14-carbon fatty acid 
chain (myristic acid) to the lysine residue at position B29 
such that each monomer bears a myristic acid side chain. 
This side chain contributes to enhanced self-association of 
insulin detemir molecules in the subcutaneous depot and 
albumin binding in the subcutaneous depot, circulation and 
the interstitial tissue, resulting in a substantial prolongation 
of action. Insulin detemir is a clear neutral solution that is 
98% albumin bound, with a duration of action of 24 hours, 
indicated for once- or twice-daily dosing, having an important 
buffering effect to limit pharmacodynamic variability.
Insulin glargine, on the other hand, is a modification of 
the amino acid sequence of human insulin, with two arginine 
residues added to the C terminus of the B-chain shifting 
the isoelectric point from pH 5.4 to 6.719. Insulin glargine 
is injected as a solute in an acidic formulation and forms a 
microprecipitate in the (neutral pH) subcutaneous tissue. 
The prolonged duration of action of this basal insulin is due 
to its slow dissolution of the precipitate which represents a 
potential source of its variability.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 33
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Heise reviewed the pharmacodynamics data of both 
insulin detemir and glargine as derived with the glucose 
clamp technique. In this review, the common definition 
for duration of action (time from injection to plasma 
glucose 8.3 mmol/L) was applied, and study data were 
recalculated when necessary. Despite differences in method-
ological details, the results of most clamp studies were very 
consistent. Both analogs demonstrated a similar “gentle rise 
and fall in glucose-lowering action” over time. The dura-
tion of action with both analogs is dose dependent, ranging 
from of 0.35 to 0.8 U/kg, and close to 24 hours in patients 
with type 1 diabetes. The dose range may be higher in type 
2 diabetes. While both analogs seem to be very similar with 
regard to the mean shape of their pharmacodynamics profile 
and duration of action, detemir demonstrates less within-
subject variability in its metabolic effect. These findings 
in experimental glucose clamp studies are consistent with 
observations in clinical trials and support routine once daily 
use with either analog.
Danne et al compared the within-subject variability of 
insulin detemir and glargine in children and adolescents 
with type 1 diabetes in a recent, doubled blind, crossover 
trial.16 Thirty-two children and adolescents (19 girls and 
13 boys; mean ± SD: age 13 ± 2.5 years and type 1 diabetes 
duration 6.3 ± 3.0 years) with a hemoglobin A1c (HbA1c) 
of 7.9% ± 1.0%, were randomized to a specific treatment 
sequence in which a dose of 0.4 U/kg of insulin detemir 
and insulin glargine was injected subcutaneously 24 hours 
apart at each of two dosing visits. Insulin detemir showed 
statistically significantly less within-subject variability com-
pared with insulin glargine for children aged 8 to 12 years 
and adolescents 13 to 17 years. No safety concerns were 
raised during the trial. In a previous euglycemic clamp study 
involving patients with type 1 diabetes, by the same authors, 
the pharmacokinetic/pharmacodynamic properties of insulin 
detemir did not differ across all age groups including adults, 
ages 18 to 65 years.17 However, there appeared to be a greater 
sensitivity for patients over the age of 65 years, suggesting 
that slightly lower dosing may be as effective.
Insulin determir: once or twice  
daily dosing
In the just published ADAPT trial, Le Floch et al showed 
no difference in efficacy between once-daily and twice-daily 
dosing of insulin detemir in 520 patients with type 1 diabetes. 
Of interest is that patients who received detemir once daily 
had a lower total daily dose than the twice-daily group.18 
In this 7-month trial, HbA1c at 4 months was 8.1 ± 0.9 vs 
8.0% ± 1.0% with qd and bid detemir, respectively, with 
an adjusted between-group difference of 0.12% (95% 
CI –0.01; 0.25%), showing non-inferiority for qd dosing. 
Similar results were found in the per protocol population. 
Improvement in HbA1c was similar in both groups (-0.4 ± 0.8 
vs -0.5% ± 0.8%; p = 0.09, NS), but with differences in the 
7-point glucose profile. Detemir doses were lower (29 ± 18 
vs 39 ± 20 U/d, p  0.001), but aspart doses higher (34 ± 17 
vs 26 ± 14 IU/d, p  0.001) with qd detemir. At 7 months, 
HbA1c decreased slightly in patients switched from qd to bid 
(8.2 ± 0.8 vs 8.0% ± 0.8%; p = 0.34, NS) in association with 
increased total insulin doses (p  0.05) but HbA1c increased 
in those switched from bid to qd (7.2 ± 0.9 vs 7.6% ± 0.8%; 
p  0.05) in association with decreased doses (p  0.05).
Efficacy: reduction of HbA1c
Insulin detemir has proven efficacy in type 1 and type 2 
diabetes. Prior to 2006 several studies compared the efficacy 
of insulin detemir in both a once- and twice-daily dosing 
regimen with NPH insulin.19–27All trials were multicenter, 
randomized, parallel-group and open-labeled. Most studies 
were conducted in patients with type 1 diabetes, and three 
large studies were conducted involving patients with type 2 
diabetes.
The Predictable Results and Experience in Diabetes 
through Intensification and Control to Target: An Inter-
national Variability Evaluation (PREDICTIVE) Study is 
a global, multi-center, open-label, observational study in 
patients with type 1 or type 2 diabetes who were transferred 
to insulin detemir for the management of their blood glucose. 
The information obtained from this trial reflects a “real world” 
experience and involves more than 30000 patients throughout 
the world. Of note, among the PREDICTIVE trials, the sub-
group analysis of the German cohort of patients with type 2 
diabetes (n = 6000),28 and the Predictive 303 study,29 dem-
onstrated superior HbA1c reduction with insulin detemir, in 
patients with type 2 diabetes, previously treated with OADs, 
alone, or in combination with NPH or glargine.
Insulin detemir-treated patients achieved a HbA1c 
reduction of 1.1% ± 0.03% (p  0.0001), achieving a mean 
HbA1c at the end of study of 7.2% ± 0.02%. When insulin 
detemir was added to OADs, HbA1c decreased 1.29% ± 0.3% 
(p  0.0001 from baseline), and those transitioning from 
NPH or glargine had an additional reduction in HbA1c of 
0.6 ± 0.9%, and 0.59% ± 0.6% (p  0.0001), respectively. 
At the end of the study, 42.2% of patients achieved a HbA1c 
of less than 7%, compared to 10.8% at baseline (p  0.0001). 
These studies demonstrate the efficacy of insulin detemir as Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 34
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the initial basal insulin for naïve patients on OADs, as well 
as more beneficial improvement in glycemic control when 
patients were switched from NPH or glargine.
The Predictive 303 study (n = 5604) evaluated the 
effectiveness of insulin detemir, using a simplified patient 
self-adjusted dosing algorithm (303 Algorithm group) com-
pared with standard-of-care physician-driven adjustments 
(Standard-of-care group) in a predominantly primary care set-
ting, over a period of 6 months. Insulin detemir was initiated 
once daily as add-on therapy to OADs, or as a replacement of 
pre-study basal insulin (NPH or glargine) in patients with type 
2 diabetes. The self-adjusted 303 Algorithm group changed 
their insulin detemir dose every 3 days based on the mean 
of three “adjusted” fasting plasma glucose (aFPG) values 
(capillary blood glucose calibrated to equivalent plasma 
glucose values) using a simple algorithm: when the mean 
aFPG is 80 mg/dL (4.4 mmol/L), reduce dose by 3 U; when 
aFPG is between 80 and 110 mg/dL (4.4–6.1 mmol/l), no 
change; when aFPG is 110 mg/dL (1.1 mmol/L), increase 
dose by 3 U. The dose of insulin detemir for patients in the 
standard-of-care group was adjusted by the investigator 
as they normally would do in their practice. Mean HbA1c 
levels decreased from 8.5% at baseline to 7.9% at 26 weeks 
for the 303 Algorithm group and from 8.5% to 8.0% for the 
Standard-of-care group (p = 0.0106 for difference in HbA1c 
reduction between the two groups).
Fasting glucose
Fasting plasma glucose (FPG) levels were significantly 
reduced in the German cohort, with mean FPG levels reduced 
by 49.8 ± 1 mg/dL (p  0.0001).
Mean FPG values decreased from 175 mg/dL at baseline 
to 141 mg/dL for the 303 Algorithm group and decreased 
from 174 mg/dL to 152 mg/dL for the Standard-of-care 
group (p  0.0001 difference in FPG reduction between 
the two groups).
Lower rate of hypoglycemia
In the German cohort, baseline total, daytime and nocturnal 
hypoglycemic events (3.3, 2.0 and 1.3 events per patient 
year, respectively) decreased by 2.7,1.6 and 1.2, respec-
tively (p  0.0001) during the study as did the percentage 
of patients experiencing these events (7.2%, 5.5% and 3.7% 
at baseline compared to 2.0%, 1.6% and 0.5% at follow up). 
In Predictive 303, the overall rate of hypoglycemia (events/
patient/year) decreased significantly from baseline in both 
groups (from 9.05 to 6.44 for the 303 Algorithm group 
(p = 0.0039) and from 9.53 to 4.95 for the Standard-of-care 
group p  0.0001). Major hypoglycemic events were rare in 
both groups (0.26 events/patient/year for the 303 Algorithm 
group and 0.20 events/patient/year for the Standard-of-care 
group; p = 0.2395).
Less weight gain
In Predictive, rather than expected weight gain, with improved 
glycemic control, overall reduction in glucose levels was 
accompanied by a 0.9 ± 0.1 kg weight reduction (p  0.0001). 
Specifically, when patients were transitioned from the three 
groups: OADs alone; OADs with NPH, or insulin glargine, 
weight reductions of 0.9 ± 0.1 kg (p  0.0001), 0.9 ± 0.3 kg 
(p = 0.00099) and 0.8 ± 0.2 kg (p  0.0001) were noted. 
Strikingly, when glycemic control improved, the rate of 
hypoglycemia and weight loss was significantly lower than 
expectations from previous studies with other basal insulins. 
In the Predictive 303 study, mean body weight remained the 
same at 26 weeks in both groups (change from baseline 0.1 
and -0.2 kg for the 303 Algorithm group and the Standard-of-
care groups respectively). At 26 weeks, 91% of the patients 
in the 303 Algorithm group and 85% of the patients in the 
Standard-of-care group remained on once-daily insulin 
detemir administration.
Interestingly, in another 52-week trial, when insulin 
detemir was titrated based on pre-breakfast and pre-dinner 
plasma glucose target of 108 mg/dL or less, the patients 
who were adjusted to twice-daily dosing had less overall 
weight loss compared to insulin glargine. If glargine had 
been titrated in the same manner to twice-daily dosing based 
on the same titration as detemir, glargine would have been 
dosed twice daily as often as detemir and possibly would 
have been higher. Nevertheless, insulin detemir had supe-
rior HbA1c reduction, less hypoglycemia, and weight gain 
was lower, 3.0 kg for detemir compared to 3.9 kg for the 
glargine group.30
The most recent Predictive BMI study was the first study 
to examine the effect of once-daily detemir with weight as 
the primary endpoint in a large population of overweight 
type 2 diabetes patients. Use of once-daily detemir for inten-
sification of insulin therapy resulted in less weight gain, less 
hypoglycemia and equivalent glycemic control compared 
with NPH.31 At 26 weeks, weight had increased significantly 
less with detemir (0.4 kg) than with NPH (1.9 kg; difference 
1.5 kg, p  0.0001). The BMI increase was also less with 
detemir than with NPH (difference 0.6 kg/m2, p  0.0001). 
The HbA1c decrease was not significantly different, from 
8.9% to 7.8% with detemir and from 8.8% to 7.8% with NPH. 
The incidence of hypoglycemia was lower with deemed Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 35
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and relative risks 0.62 (all events) and 0.43 (nocturnal) 
(p  0.0001 for both).
Conclusion
Insulin detemir is the most suitable basal analog insulin, 
with lower within-patient variability, and consistent reduc-
tions in FPG levels. The pharmocokinetic/pharmacodynamic 
properties of insulin detemir have demonstrated lower rates 
of hypoglycemia and weight gain, making it an ideal choice 
to manage patients with diabetes.
Trials intended to reduce cardiovascular risk should 
continue to explore the benefits of intensification and 
normalization of glucose levels. The management of these 
patients with type 2 diabetes should be simplified with 
metformin alone and insulin detemir with the intention of 
focusing on hypoglycemic events. Another consideration 
in the future will be to analyze the total daily insulin dose 
and, specifically, to limit the total basal insulin dose to less 
than 50% of total, and ideally less than 0.5 U/kg, since 
this has been associated with superior glycemic control, 
lower fasting glucose levels and less weight gain.32 Insulin 
detemir should be given strong consideration as basal insulin 
diabetes management. Recent information is compelling to 
suggest this basal analog insulin as the agent of choice in 
type 2 diabetes.
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